Press release Stine Krag Brunvold 10/11/24 Press release Stine Krag Brunvold 10/11/24 NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Read More Press release Stine Krag Brunvold 7/11/24 Press release Stine Krag Brunvold 7/11/24 NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Read More Press release Stine Krag Brunvold 6/18/24 Press release Stine Krag Brunvold 6/18/24 NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Read More Press release Stine Krag Brunvold 6/11/24 Press release Stine Krag Brunvold 6/11/24 NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Read More Press release Stine Krag Brunvold 3/22/24 Press release Stine Krag Brunvold 3/22/24 NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Read More Press release Stine Krag Brunvold 3/21/24 Press release Stine Krag Brunvold 3/21/24 NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine Read More Press release Stine Krag Brunvold 3/1/24 Press release Stine Krag Brunvold 3/1/24 NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences Read More Press release Stine Krag Brunvold 1/22/24 Press release Stine Krag Brunvold 1/22/24 NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services Read More Press release Stine Krag Brunvold 11/15/23 Press release Stine Krag Brunvold 11/15/23 NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing Read More Press release Stine Krag Brunvold 10/3/23 Press release Stine Krag Brunvold 10/3/23 NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society Read More Press release Stine Krag Brunvold 9/26/23 Press release Stine Krag Brunvold 9/26/23 NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Read More Press release Stine Krag Brunvold 9/8/23 Press release Stine Krag Brunvold 9/8/23 NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association Read More Press release Stine Krag Brunvold 6/20/23 Press release Stine Krag Brunvold 6/20/23 NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Read More Press release Stine Krag Brunvold 6/9/23 Press release Stine Krag Brunvold 6/9/23 NMD Pharma to Present Results from the Charcot-Marie-Tooth ESTABLISH Study at the Peripheral Nerve Society Annual Meeting Read More Press release Stine Krag Brunvold 6/1/23 Press release Stine Krag Brunvold 6/1/23 NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy Read More Press release Stine Krag Brunvold 5/23/23 Press release Stine Krag Brunvold 5/23/23 NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 Read More Press release Stine Krag Brunvold 1/3/23 Press release Stine Krag Brunvold 1/3/23 Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Read More Press release Stine Krag Brunvold 12/14/22 Press release Stine Krag Brunvold 12/14/22 NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Read More Press release Stine Krag Brunvold 10/11/22 Press release Stine Krag Brunvold 10/11/22 NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Read More Press release Stine Krag Brunvold 9/27/22 Press release Stine Krag Brunvold 9/27/22 FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis Read More Older Posts
Press release Stine Krag Brunvold 10/11/24 Press release Stine Krag Brunvold 10/11/24 NMD Pharma to Present Data on its Skeletal Muscle Targeted Therapy for Rare Neuromuscular Diseases at the 2024 AANEM Annual Meeting Read More
Press release Stine Krag Brunvold 7/11/24 Press release Stine Krag Brunvold 7/11/24 NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Read More
Press release Stine Krag Brunvold 6/18/24 Press release Stine Krag Brunvold 6/18/24 NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Read More
Press release Stine Krag Brunvold 6/11/24 Press release Stine Krag Brunvold 6/11/24 NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Read More
Press release Stine Krag Brunvold 3/22/24 Press release Stine Krag Brunvold 3/22/24 NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Read More
Press release Stine Krag Brunvold 3/21/24 Press release Stine Krag Brunvold 3/21/24 NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine Read More
Press release Stine Krag Brunvold 3/1/24 Press release Stine Krag Brunvold 3/1/24 NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences Read More
Press release Stine Krag Brunvold 1/22/24 Press release Stine Krag Brunvold 1/22/24 NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services Read More
Press release Stine Krag Brunvold 11/15/23 Press release Stine Krag Brunvold 11/15/23 NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing Read More
Press release Stine Krag Brunvold 10/3/23 Press release Stine Krag Brunvold 10/3/23 NMD Pharma to present NMD670 clinical data from a Phase I/IIa trial in myasthenia gravis at the 28th International Annual Congress of the World Muscle Society Read More
Press release Stine Krag Brunvold 9/26/23 Press release Stine Krag Brunvold 9/26/23 NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy Read More
Press release Stine Krag Brunvold 9/8/23 Press release Stine Krag Brunvold 9/8/23 NMD Pharma to host a Satellite Symposium and present new clinical data at the 148th Annual Meeting of the American Neurological Association Read More
Press release Stine Krag Brunvold 6/20/23 Press release Stine Krag Brunvold 6/20/23 NMD Pharma Reports Results from the ESTABLISH Study – an International Observational Study of Neuromuscular Function in Charcot-Marie-Tooth Type 1 and 2 Read More
Press release Stine Krag Brunvold 6/9/23 Press release Stine Krag Brunvold 6/9/23 NMD Pharma to Present Results from the Charcot-Marie-Tooth ESTABLISH Study at the Peripheral Nerve Society Annual Meeting Read More
Press release Stine Krag Brunvold 6/1/23 Press release Stine Krag Brunvold 6/1/23 NMD Pharma appoints Daniel Brennan as SVP, Corporate and Commercial Strategy Read More
Press release Stine Krag Brunvold 5/23/23 Press release Stine Krag Brunvold 5/23/23 NMD Pharma initiates Phase I safety, tolerability and pharmacokinetics study of NMD1343 Read More
Press release Stine Krag Brunvold 1/3/23 Press release Stine Krag Brunvold 1/3/23 Mike Heffernan appointed Chairman of NMD Pharma’s Board of Directors Read More
Press release Stine Krag Brunvold 12/14/22 Press release Stine Krag Brunvold 12/14/22 NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Read More
Press release Stine Krag Brunvold 10/11/22 Press release Stine Krag Brunvold 10/11/22 NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Read More
Press release Stine Krag Brunvold 9/27/22 Press release Stine Krag Brunvold 9/27/22 FDA grants Orphan Drug Designation for NMD670 for the Treatment of Myasthenia Gravis Read More
